A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Ollinger, Juliane ^a   Bailey, Mai Ann ^a   Moraski, Garrett C ^b   Casey, Allen ^a   Florio, Stephanie ^a   Alling, Torey ^a   Miller, Marvin J ^b   Parish, Tanya ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ETHAMBUTOL; ETHIONAMIDE; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; ISONIAZID; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL COUNT; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; FLUORESCENCE; MINIMUM INHIBITORY CONCENTRATION; MONITORING; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTICAL DENSITY; STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; GENE EXPRESSION REGULATION, BACTERIAL; GENES, REPORTER; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 84875954380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060531     Document Type: Article

References (34)

1. WHO (2010) WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 18: 237.
2. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C, (2012) Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases 54: 579-581.
3. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, et al. (2012) Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Ag Chemother 56: 3027-3031.
4. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, et al. (2011) Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. International Journal of Tuberculosis and Lung Disease 15: 949-954.
5. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, et al. (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373: 1183-1189.
6. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, et al. (2003) Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clinical Infectious Diseases 37: 1448-1452.
7. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, et al. (1996) Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Ag Chemother 40: 2655-2657.
8. Mitchison D, Davies G, (2012) The chemotherapy of tuberculosis: past, present and future. International Journal of Tuberculosis and Lung Disease 16: 724-732.
9. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc 6: 29-40.
10. Ma Y, Stern RJ, Scherman MS, Vissa VD, Yan W, et al. (2001) Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Ag Chemother 45: 1407-1416.
11. Scherman MS, Winans KA, Stern RJ, Jones V, Bertozzi CR, et al. (2003) Drug targeting Mycobacterium tuberculosis cell wall synthesis: development of a microtiter plate-based screen for UDP-galactopyranose mutase and identification of an inhibitor from a uridine-based library. Antimicrob Ag Chemother 47: 378-382.
12. Reynolds RC, Ananthan S, Faaleolea E, Hobrath JV, Kwong CD, et al. (2012) High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 92: 72-83.
13. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89: 334-353.
14. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, et al. (2010) A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1: 57.
15. Sirgel FA, Wiid IJF, van Hleden PD (2008) Measuring minimum inhibitory concentrations in mycobacteria. In: Parish T, Brown AC, editors. Mycobacteria Protocols. New York: Humana Press. 173-186.
16. Nilsson LE, Hoffner SE, Ansehn S, (1988) Rapid susceptibility testing of Mycobacterium tuberculosis by bioluminescence assay of mycobacterial ATP. Antimicrob Ag Chemother 32: 1208-1212.
17. Cooksey RC, Crawford JT, Jacobs WR Jr, Shinnick TM, (1993) A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Ag Chemother 37: 1348-1352.
18. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 24: e10777.
19. Collins L, Franzblau SG, (1997) Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Ag Chemother 41: 1004-1009.
20. Foongladda S, Roengsanthia D, Arjrattanakool W, Chuchottaworn C, Chaiprasert A, et al. (2002) Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis. International Journal of Tuberculosis and Lung Disease 6: 1118-1122.
21. Andreu N, Fletcher T, Krishnan S, Robertson BD, (2012) Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67: 404-414.
22. Changsen C, Franzblau SG, Palittapongarnpim P, (2003) Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob Ag Chemother 47: 3682-3687.
23. Collins LA, Torrero MN, Franzblau SG, (1998) Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob Ag Chemother 42: 344-347.
24. Gruppo V, Johnson CM, Marietta KS, Scherman H, Zink EE, et al. (2006) Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob Ag Chemother 50: 1245-1250.
25. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, et al. (2010) Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 5: e9823.
26. Moraski GC, Markley LD, Chang M, Cho S, Franzblau SG, et al. (2012) Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds. Bioorg Med Chem 20: 2214-2220.
27. Moraski GC, Markley LD, Hipskind PA, Boshoff H, Cho S, et al. (2011) Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med Chem Lett 2: 466-470.
28. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, et al. (2013) Fueling open-source drug discovery: 177 smal-molecule leads against tuberculosis. Chem Med Chem 8: 313-321.
29. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM, et al. (2010) Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 192: 3645-3653.
30. Lambert RJ, Pearson J, (2000) Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol 88: 784-790.
31. Lilly NaE (2004-) Assay Guidance Manual. In: Sittampalam GS, Gal-Edd N, Arkin M, Auld D, Austin CP et al., editors. Bethesda: Eli Lilly & Company and the National Center for Advancing Translational Sciences.
32. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, et al. (2012) Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92: 453-488.
33. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, et al. (2009) Antituberculosis activity of the molecular libraries screning center network library. Tuberculosis (Edinb) 89: 354-363.
34. Simeonov A, Jadhav A, Thomas CJ, Wang Y, Huang R, et al. (2008) Fluorescence spectroscopic profiling of compound libraries. J Med Chem 51: 2363-2371.